Gaps Between ICH Q7 and China's GMPs Described
This article was originally published in The Gold Sheet
While the Chinese GMPs for API suppliers have more stringent requirements governing personnel and sterility requirements for cleanrooms, the ICH Q7 guideline has stricter rules for in-process controls and reprocessing of solvents, according to Li Ting of DSM Anti-Infectives. She discussed these "gaps" at the 11 APIC/CEFIC European conference on APIs Oct. 23 in Paris. Ting works for DAI China, a new business unit of DSM. DAI China is located in Beijing, with two facilities in northern China that manufacture penicillin and cephalosporin products
You may also be interested in...
The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.
Medicinal products authorities will consider a medtech notified body opinion on the device element of a drug/device combination product. A new position paper explains how roles and responsibilities are shared between medtech and medicinal product experts.
A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.